Victor Chong

Company: Clearside Biomedical

Job title: Chief Medical Officer & Executive Vice President

Seminars:

Panel Discussion: What Are the Key Considerations for Advancing Drug Delivery in Retinal Disease & How Can We Overcome the Challenges? 11:30 am

What are the comparative strengths and weaknesses of current drug delivery innovations, such as suprachoroidal injections, topical treatments, oral drugs, and implants? How do these different delivery methods impact treatment effectiveness and safety profiles, and what trade-offs do they present? What practical challenges do these diverse approaches face, and how do they stack up in…Read more

day: Day Two

Transforming wAMD Treatment: Long-Lasting, Flexible Dosing with Suprachoroidal TKI Delivery 9:00 am

Address the high treatment burden of current anti-VEGF therapies for wAMD, highlighting the need for more sustainable and less frequent treatment but maintain the flexibility of anti-VEGF biologics Explore the benefits of TKIs in wAMD management, focusing on their pan-VEGF receptors blockage, extended drug delivery while acknowledging the limitations of current intravitreal anti-VEGF due to…Read more

day: Day Two